INSIGHTS ON CLINICAL TRIAL PARTNERING
-
![GettyImages-1987435635 research, planning]( "Rescuing A Global Program For NDA Success")
Rescuing A Global Program For NDA SuccessExplore the collaboration that enabled FDA approval of a novel chronic-condition therapy, rescued a high-risk program, and demonstrated a unified “one-team” approach by reworking the sponsor's SAP.
-
![iStock-1208998537-meeting-talking-business]( "Transform Relationship Management Into A Strategic Advantage")
Transform Relationship Management Into A Strategic AdvantageDiscover how you can transform data management into a relationship-driven capability with the right partnership, achieving confidence, agility, and insight across the clinical trial lifecycle.
-
![adaptive clin trials bucket]( "Adaptive Clinical Trials")
Adaptive Clinical TrialsAn adaptive study design can be especially useful if there are uncertainties specific to your drug. Adjusting your study as data accumulates means getting answers sooner.
-
![AI, artificial intelligence-GettyImages-2205274485]( "Early-Stage Biotech's AI Advantage Is A Window That Closes")
Early-Stage Biotech's AI Advantage Is A Window That ClosesThe "greenfield" advantage allows biotechs to build AI-native trials from the start, replacing manual data entry with automated workflows and structured human oversight for better data integrity.
-
The Rise Of Targeted Modalities In Pharmaceutical Development8/11/2025
Targeted modalities are pushing the boundaries of technology and therapeutic effectiveness. Their potential to transform patient care depends on leveraging the right expertise, technologies, and partnerships.
-
Building A Gold Standard Trial Experience In Japan4/4/2025
Hear how Medable worked with a Japanese sponsor to elevate their trial experience, achieve >90% patient and site adherence, and beat their forecasted FPI date, creating new eCOA standards adopted across all the customer’s vendors.
-
Multi-Site Capabilities For Your Phase I-II Trials5/1/2026
Master the complexities of renal and hepatic trials by leveraging site expertise and PK modeling to navigate recruitment challenges and ensure precise dosing for impaired patient populations.
-
Site Engagement Improves Study Support And Results12/10/2025
Dedicated site engagement helps reduce administrative burden, improve participant access, and keep studies moving. This approach strengthens workflows and supports sites throughout every phase.
-
Elevating The Site Voice3/27/2025
A decentralized trial can be daunting for sites, but Medidata offers solutions to help site staff, sponsors, and patients move smoothly through the clinical trial process.
CLINICAL TRIAL PARTNERING SOLUTIONS
-
![Iqvia one home thumb]( "It's Time To Move Into One Home for Sites")
Explore a vendor- and sponsor-neutral platform that streamlines trial management by consolidating systems and tasks.
-
![An Insider’s Guide To Interactive Response Technology (IRT) For Clinical Trials]( "IQVIA Clinical Trial Payments")
Our site payments portal provides complete transparency, allowing you to fully outsource your payment operations to our experts or adopt a customizable hybrid model.
-
![GettyImages-1083316464_eye]( "Your Top Partner For Ophthalmic Drug Development")
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.
-
![GettyImages-1332585814 oncology patient nurse]( "Your Partners In Drug Development And Safety")
How can Ergomed use its oncology expertise, global reach, and access to patients with rare and ultra-rare diseases can help your organization achieve efficient, high-quality clinical trial execution?
-
![GettyImages-1213797500 doctor cancer patient, oncology]( "Early-Phase Oncology Research Expertise")
Our priority is guiding promising therapies to proof-of-concept with precision and urgency, because every day saved in development matters profoundly to patients living with cancer.
